D. Cameron

发表

University of Birmingham Strategies to improve recruitment to a de-escalation trial

L. Hughes-Davies, A. Marshall, J. Dunn, 2020 .

Code of practice needed for samples donated by trial participants.

A. Howell, M. Dowsett, M. Piccart, 2022, The Lancet. Oncology.

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

L. Esserman, S. Edge, L. Pusztai, 2021, The Lancet. Oncology.

Multi-omic machine learning predictor of breast cancer therapy response

F. Markowetz, S. Chin, C. Caldas, 2021, Nature.

Histological grading of invasive breast carcinoma – a simplification of existing methods in a large conservation series with long‐term follow‐up

John M S Bartlett, G. Kerr, U. Chetty, 2009, Histopathology.

The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation

E. Provenzano, H. Earl, D. Rea, 2019, Journal of clinical epidemiology.

Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.

C. Desmedt, D. Larsimont, C. Caldas, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study

J. Bartlett, C. Poole, L. Hopcroft, 2023, Breast Cancer Research and Treatment.

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results

H. Earl, D. Miles, A. Wardley, 2018, BMC Cancer.

Evidence needs for licensing and reimbursement

R. Edlin, C. McCabe, P. Hall, 2013 .

Consolidated criteria for reporting qualitative research guidelines

J. Donovan, S. Pinder, A. Makris, 2016 .

Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial.

J. Donovan, S. Pinder, H. Earl, 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

Chromosome instability and benefit from adjuvant anthracyclines in breast cancer

J. Bartlett, D. Cameron, A. Munro, 2012, British Journal of Cancer.

Strategies to Improve Recruitment to a De-escalation Trial: A Mixed-Methods Study of the OPTIMA Prelim Trial in Early Breast Cancer

J. Donovan, S. Pinder, D. Rea, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

Optima: Optimal personalised treatment of early breast cancer using multi-parameter analysis, an international randomized trial of tumor gene expression test-directed chemotherapy treatment in a largely node-positive population.

B. Kiely, D. Rea, B. Naume, 2021 .

Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge

J. Bartlett, D. Cameron, A. Munro, 2010, Oncogene.